Cosette Pharmaceuticals
Privately held: no public share price
Assets
(4 total)
4Total Assets
3Approved
0Phase 3 / Filed
1Phase 1–2 / Early
6Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Approved | GABA-A receptor (benzodiazepine site)Small molecule | EpilepsyDevelopmental and Epileptic EncephalopathiesLennox-Gastaut Syndrome | |
Colesevelam(Welchol) | Approved | Bile acid sequestrantSmall molecule | Type 2 Diabetes |
| Approved | Nonsteroidal Anti-inflammatory DrugSmall molecule | Migraine | |
bremelanotide(Vyleesi) | Phase 2 | MC4RPeptide | Obesity |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
31 March 2025Topline resultbremelanotideBMT-801 Phase 2 obesity co-administration study meets primary endpoint
Q1 2025Topline resultbremelanotidePhase 2 of bremelanotide with tirzepatide met its primary endpoint
Financial reports
No financial reports recorded.